Back to search results

High Dose-Rate Brachytherapy for Liver Malignancies

This study is testing a treatment called high dose-rate brachytherapy (HDRBT) for people with liver tumors that cannot be removed by surgery. This includes both primary liver cancers (cancers that start in the liver) and secondary liver cancers (cancers that spread to the liver), such as metastatic cholangiocarcinoma, pancreatic cancer, and melanoma. Researchers want to see how well HDRBT controls these tumors compared to past patients who didn't receive this treatment. You might be able to join if you are over 18 and have up to five tumors in your liver that are at least 3 cm in size and are close to important blood vessels or other sensitive organs. The study aims to enroll 60 participants.

Study design
This interventional study plans to enroll 60 participants. It will compare the effectiveness of HDRBT in current patients to a group of historical patients.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to evaluate treatment effectiveness for an average of 1 year, with tumor control rates also compared at 3-month intervals.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05053555

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Recruiting
NAAges 19+InterventionalTreatment
M.D. Anderson Cancer Center
~60 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:high dose rate brachytherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.
Measured over Through study completion, an average of 1 year

Conditions

Liver Malignant Tumors
Cholangiocarcinoma Metastatic
Pancreatic Cancer
Melanoma

Explore related trials

CholangiocarcinomaMalignant Liver NeoplasmMelanomaPancreatic Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Joshua Kuban · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Joshua Kuban
[email protected]
713-745-0944
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

GROUP A: Patients with liver lesions must be over the age of 18
GROUP A: Any patient with up to five unresectable tumors that are:
At least 3 cm (largest diameter in the axial plane)
In close proximity to large blood vessels
In close proximity to sensitive structures (bowel, stomach, diaphragm, liver capsule, liver hilum, bile ducts)
Associated with difficult endovascular access to one or more feeding arterial branches (hypovascular tumors)
Associated with a large shunt fraction to other vital organs
GROUP B: Historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021

Exclusion

Active infectious disease
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Patients with polymetastatic disease with the exception of those patients who may benefit from therapy addressing local complications directly related to the target lesion diminishing quality of life such as pain, vascular/biliary occlusion, and liver disfunction
Pregnancy (sexually active patients must be on birth control while participating in this study)
Child-Pugh class C
Total serum bilirubin \> 2 mg/dl
Platelet count \< 50,000/ul
International normalized ratio (INR) \> 1.5

What this trial measures

  • To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.Through study completion, an average of 1 year